The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:740-741 August 18, 2005 Number 7
NextNext

Response of a Nonmalignant Pleural Effusion to Bevacizumab

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: The potential role of vascular endothelial growth factor in malignant as well as nonmalignant pleural effusion1,2 prompted us to use bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in a 68-year-old man with primary cardiac amyloidosis who had severe dyspnea and underwent repeated thoracenteses for pleural effusions. Cytologic assessments of the pleural fluid did not detect malignant cells. Primary amyloidosis had been diagnosed by myocardial biopsy four weeks previously, but there were no other manifestations of amyloidosis. At the time of the patient's admission, left ventricular function was moderately reduced (ejection fraction, 40 percent). A radiograph . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.